MARKET WIREYahoo Finance • 21h ago
Is Avantor (AVTR) Stock Outpacing Its Medical Peers This Year?Yahoo Finance report covering Avantor Inc. (AVTR) market action, institutional positioning, and fundamental catalysts.
Why AVTR Stock dropped -2.74% Today — RQD Quant Desk Flash
$15.61 -2.74% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $15.50
Avantor Inc. (AVTR) carries a Roarable Rating of D+ (Sell) with 56/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D+ • SELL / AVOID
Cap $10.88B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on AVTR Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is AVTR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Avantor Inc. (NYSE: AVTR) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 56/100 at a spot price of $15.61 (-2.74% 1D, market cap $10.88B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 15/20, SEC Balance-Sheet Forensics 9/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 11/20. Across 1015 tracked Health Care issuers, AVTR ranks #194 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does AVTR compare to BIO and TXG in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), AVTR carries a Roarable D+ (56/100 RQD), trailing P/E of N/A, gross margin of 32.7%, and ROIC of -2.1%. By comparison, BIO (Bio-Rad Laboratories Inc.) holds a C grade (62/100 RQD, P/E 13.5x, ROIC 0.5%, cap $9.95B) and TXG (10x Genomics Inc.) posts a C- grade (59/100 RQD, P/E N/A, ROIC -5.7%, cap $9.13B). Among the 5-stock peer group, BIO leads on earnings multiple (13.5x) while RVTY leads on capital efficiency (3.1% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for AVTR?
▼
Per AVTR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001722482), Avantor Inc. generated $6.55B in revenue (-3.4% YoY), -$530.2M in net income, and $495.0M in free cash flow against $11.79B in total assets and $3.92B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $15.50 (-0.68%)🧬 Cannibal Buyback (-0.96% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 7.6% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 56/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.4% avg 90D alpha vs SPY • 51.8% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D+
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw C- · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-0.9% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AVTR)Realized 20D OHLCV Swing Band: ±6.3%
Deterministic 5-Pillar Attribution (56/100 Composite)
🔍 WHY AVTR SCORES 56/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+15/20 pts (27% of score)
20D Institutional Volume Accumulation (±6.3% realized swing band)
▲ #2 Bullish Driver: Macro Regime Fit+11/20 pts (20% of score)
FRED Regime × Technicals: 82% of 52W Range • RSI-14 at 48.3 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: SEC 10-K Forensic Risk9/20 pts (-11 pt drag)
Balance-sheet & 10-K footnote risk deducts 11 pts from forensic ceiling
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C+$15.70+9.9% Next Q
64
Q2 (-2Q)Grade C$17.26-3.3% Next Q
61
Q3 (-1Q)Grade C$16.69-6.5% Next Q
59
CurrentGrade D+$15.61-0.4% Hist 90D α
56
Trajectory: C+ (64) → D+ (56)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the AVTR Bull Thesis Could Fail
Even with a 56/100 (D+) score, AVTR faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Cannibal Buyback (-0.96% YoY Shares) — any gross margin slip below 30.2% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($15.62) or 200D SMA ($11.26) invalidates the momentum regime and cuts Target Base ($15.47) toward Bear Floor ($12.07).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $AVTR• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “AVTR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why AVTR Stock dropped -2.74% Today — RQD Quant Desk Flash
Avantor Inc. (AVTR) dropped -2.74% to $15.61, trading at 82% of its 52-week range ($7.26 – $17.45). Stretched risk/reward at current multiples (-2% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 82% of its 52-week range ($7.26 – $17.45) with RSI-14 at 48.3 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±6.3% around $15.61 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D+ (Sell) backed by 32.7% gross margin and $495.0M annual free cash flow.
Live AVTR Headlines & Catalysts
CATALYSTYahoo Finance • 1d ago
Avantor (AVTR) is Regaining Market ConfidenceYahoo Finance report covering Avantor Inc. (AVTR) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESeeking Alpha • 1d ago
Avantor, Inc. 2026 Q3 - Results - Earnings Call Presentation (NYSE:AVTR) 2026-10-28Seeking Alpha report covering Avantor Inc. (AVTR) market action, institutional positioning, and fundamental catalysts.
CATALYSTGuruFocus • 1d ago
Is Avantor Inc (AVTR) Overvalued After 3.9% Rally? GF Value SaysGuruFocus report covering Avantor Inc. (AVTR) market action, institutional positioning, and fundamental catalysts.
RISK WATCHSimply Wall St • 1d ago
Avantor (AVTR) Stock Looks Fairly Valued After a 56% Five Year FallSimply Wall St report covering Avantor Inc. (AVTR) market action, institutional positioning, and fundamental catalysts.
RISK WATCHYahoo Finance • 1d ago
Avantor (AVTR) Stock Drops As Q3 Earnings Rebound Meets CautionYahoo Finance report covering Avantor Inc. (AVTR) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
Here's Why You Should Add Avantor Stock to Your Portfolio for NowYahoo Finance report covering Avantor Inc. (AVTR) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
3 Reasons to Sell AVTR and 1 Stock to Buy InsteadYahoo Finance report covering Avantor Inc. (AVTR) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo • 21h ago
Cell and Tissue Culture Supplies - Global Strategic Business Report: Capitalize on the US$97.7 Billion Surge as Avantor, Corning, Lonza, and Thermo Fischer Scientific Reshape CompetitionBoost ROI through automation, 3D culture and specialty media that enhance throughput, reproducibility and drug-screening accuracy while reducing manual work and animal testing.Dublin, Nov. 02, 2026 (GLOBE NEWSWIRE) -- "C
MARKET WIREYahoo • 3d ago
Avantor, Inc. (AVTR) is a Great Momentum Stock: Should You Buy?Does Avantor, Inc. (AVTR) have what it takes to be a top stock pick for momentum investors? Let's find out.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AVTR)
- ✓Walkthrough of AVTR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
AVTR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +95.37%🛡️ HOLDING TREND SUPPORT
2026-11-03O $16.68H $16.68L $15.61C $15.61VOL 9.73M
RES: $17.87SUP: $15.54SMA50: $15.62SMA200: $11.26
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
AVTR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
23.9%/yr Implied 5Y Growth
vs. -3.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on AVTR today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for AVTR. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for AVTR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AVTR)
Health Care Rank #194 of 1015
⚔️ BIO vs AVTR Full Matrix →
1. Head-to-Head Health Care Peer Comparison (AVTR vs. BIO, TXG, BRKR, RVTY)
Industry: Biotechnology: Laboratory Analytical Instruments (21 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Avantor Inc. (AVTR) ranks #194 by composite RQD confidence (56/100, grade D+) and #98 by equity capitalization ($10.88B). Within this direct 5-issuer industry benchmark cohort, BIO leads on earnings valuation at 13.5x trailing P/E, while RVTY leads on capital efficiency and profitability with 3.1% ROIC and — gross margin. RVTY currently holds the highest overall quantitative score in the immediate peer group at 65/100 (C) compared with AVTR at 56/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| AVTR
ACTIVE
Avantor Inc. | D+ | 56/100 | — | 32.7% | -2.1% | -2.74% | $10.88B | Benchmark Subject |
| BIO Bio-Rad Laboratories Inc. | C | 62/100 | 13.5x | 51.9% | 0.5% | -1.62% | $9.95B | /bio-vs-avtr → |
| TXG 10x Genomics Inc. | C- | 59/100 | — | 69.1% | -5.7% | -12.09% | $9.13B | /txg-vs-avtr → |
| BRKR Bruker Corporation | D+ | 54/100 | — | 45.9% | 1.3% | -2.42% | $8.70B | /brkr-vs-avtr → |
| RVTY Revvity Inc. | C | 65/100 | 76.7x | — | 3.1% | -3.44% | $17.52B | /rvty-vs-avtr → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001722482 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Avantor Inc. (AVTR) reported GAAP revenue of $6.55B (-3.4% vs. FY2024 revenue of $6.78B , and -6.0% cumulative change since FY2023) , GAAP net income of -$530.2M, operating cash flow of $623.8M, and free cash flow of $495.0M (-28.5% YoY). On the balance sheet, AVTR closed FY2025 with $11.79B in total assets against $3.92B in total debt (Altman Z-Score: 1.88, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $6.55B | -$530.2M | $623.8M | $495.0M | $11.79B | $3.92B |
| FY2024 (FY) | 2024-12-31 | $6.78B | $711.5M | $840.8M | $692.0M | $12.11B | $3.23B |
| FY2023 (FY) | 2023-12-31 | $6.97B | $321.1M | $870.0M | $556.5M | $8.36B | $1.96B |
3. AVTR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs AVTR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Avantor Inc. (NYSE: AVTR) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 56/100 at a spot price of $15.61 (-2.74% 1D, market cap $10.88B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 15/20, SEC Balance-Sheet Forensics 9/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 11/20. Across 1015 tracked Health Care issuers, AVTR ranks #194 in composite RQD confidence.
How does AVTR compare to BIO and TXG in the Health Care sector?
Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), AVTR carries a Roarable D+ (56/100 RQD), trailing P/E of N/A, gross margin of 32.7%, and ROIC of -2.1%. By comparison, BIO (Bio-Rad Laboratories Inc.) holds a C grade (62/100 RQD, P/E 13.5x, ROIC 0.5%, cap $9.95B) and TXG (10x Genomics Inc.) posts a C- grade (59/100 RQD, P/E N/A, ROIC -5.7%, cap $9.13B). Among the 5-stock peer group, BIO leads on earnings multiple (13.5x) while RVTY leads on capital efficiency (3.1% ROIC).
What are the biggest fundamental strengths and SEC risk factors for AVTR?
Per AVTR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001722482), Avantor Inc. generated $6.55B in revenue (-3.4% YoY), -$530.2M in net income, and $495.0M in free cash flow against $11.79B in total assets and $3.92B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins. Institutional options positioning shows a 50% call / 50% put premium split.
Where is AVTR trading relative to its 50-day, 200-day, and 52-week technical levels?
AVTR last traded at $15.61 (-2.74% on volume of 9,404,283 shares), positioning the stock -0.06% below its 50-day simple moving average ($15.62) and +38.63% above its 200-day simple moving average ($11.26). Across its 52-week range of $7.26 to $17.45, AVTR sits at the 81.9% percentile with a 14-day RSI of 48.3 (NEUTRAL RANGE) and an implied next-earnings move of ±6.3% ($14.63 to $16.59).
ROARABLE RATING BRIEF • RQD 56/100 (D+)
✓ SEC XBRL & RQD VERIFIED
AVTR — Avantor Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Avantor Inc. (AVTR) earns a live Roarable RQD composite score of 56/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $15.61 (-2.74% 1D, market capitalization $10.88B).
- Fundamental Cash Engine (10/20): Anchored by return on invested capital (ROIC) of -2.1%, gross margin of 32.7%, operating margin of -3.8%, and free cash flow yield of 4.38%.
- Whale 13F & Options Flow (15/20) + Insider Conviction (11/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (11/20) + Forensic Balance Sheet (9/20): Incorporates a 1.01x equity beta, Altman Z-Score of 1.88, Piotroski F-Score of 5/9, and Debt/Equity of 0.70x.
2. Business Model, Unit Margins & SEC Financial Trajectory
Avantor Inc. Is a NYSE-listed issuer classified under the Health Care sector and Biotechnology: Laboratory Analytical Instruments industry,. The source data provides a market capitalization of $11.3B. Gross margin is 32.7% per the market data.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Avantor Inc. (AVTR) reported $6.55B in annual revenue (up from $6.78B in FY2024, -3.4% YoY) and -$530.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($6.97B revenue, $321.1M net income) through FY2025, AVTR scaled operating cash flow to $623.8M and free cash flow to $495.0M, backed by $11.79B in total assets against $3.92B in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D+ • RQD 56/100): Big institutional funds and options desks are actively positioning on the bullish side. Free cash flow yield of 4.38% and institutional whale pillar of 15/20. With Fundamental Cash Engine at 10/20 and Institutional Whale Flow at 15/20, sustained execution supports upside toward the upper end of the $7.26 – $17.45 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins. Investors must weigh current valuation against -3.8% operating margins and a 1.01x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
The only sector context provided is Health Care / Biotechnology: Laboratory Analytical Instruments.
- Key Question #1: Can AVTR sustain or expand its -3.8% operating margin and -2.1% ROIC against Biotechnology: Laboratory Analytical Instruments peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $6.55B and free cash flow of $495.0M, how will capital allocation balance growth reinvestment against $3.92B in total debt?
- Key Question #3: How sensitive is AVTR's 31.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.01x)?
AVTR Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Avantor Inc. (AVTR) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 21h ago
Is Avantor (AVTR) Stock Outpacing Its Medical Peers This Year? Yahoo Finance report covering Avantor Inc. (AVTR) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Yahoo Finance • 1d ago
Avantor (AVTR) is Regaining Market Confidence Yahoo Finance report covering Avantor Inc. (AVTR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Seeking Alpha • 1d ago
Avantor, Inc. 2026 Q3 - Results - Earnings Call Presentation (NYSE:AVTR) 2026-10-28 Seeking Alpha report covering Avantor Inc. (AVTR) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST GuruFocus • 1d ago
Is Avantor Inc (AVTR) Overvalued After 3.9% Rally? GF Value Says GuruFocus report covering Avantor Inc. (AVTR) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Simply Wall St • 1d ago
Avantor (AVTR) Stock Looks Fairly Valued After a 56% Five Year Fall Simply Wall St report covering Avantor Inc. (AVTR) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Yahoo Finance • 1d ago
Avantor (AVTR) Stock Drops As Q3 Earnings Rebound Meets Caution Yahoo Finance report covering Avantor Inc. (AVTR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Here's Why You Should Add Avantor Stock to Your Portfolio for Now Yahoo Finance report covering Avantor Inc. (AVTR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
3 Reasons to Sell AVTR and 1 Stock to Buy Instead Yahoo Finance report covering Avantor Inc. (AVTR) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
AVTR Bull vs. Bear Conversation Board — What's Your Call at $15.61?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON AVTR 🐻 33% BEARISH CONVICTION
MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH
🎯 Target: $19.10 (+19.0%)
📌 Pinned Debate Institutional whale flow scores 18/20 and the FCF yield of 4.38% shows the business still generates cash relative to its market value.
Don't sleep on AVTR's setup in Health Care. Institutional whale flow scores 18/20 and the FCF yield of 4.38% shows the business still generates cash relative to its market value.. Beta of 1.01 means it moves fast when momentum turns, and the 5-pillar RQD gauge (56/100) backs up the fundamental quality.
SectorRotator 🐂 BULL
@ShortSeller_Dan Fair point on 31.0x forward P/E, but you're ignoring the forward operating leverage in Biotechnology: Laboratory Analytical Instruments. If gross margin (32.7%) holds, EPS grows into the multiple faster than bears think.
SH ShortSeller_Dan RQD DEBATE OPENER • Forensic Short Bias 🐻 BEARISH
🎯 Target: $13.00 (-19.0%)
Spot @ $16.05 ROIC of -2.1%, FY 2025 net loss of -$530.2M, and debt rising to $3.92B against an Altman Z of 1.88 point to a weak return profile and
I respect the product at Avantor Inc., but the stock at $16.05 is a different story. ROIC of -2.1%, FY 2025 net loss of -$530.2M, and debt rising to $3.92B against an Altman Z of 1.88 point to a weak return profile and balance-sheet strain.. FCF yield is 4.38% and RQD sits at 56/100 (D+) — why pay up here when you can wait for next quarter's numbers?